Peter Diamandis
Episode overview

Martine Rothblatt: Growing Unlimited Organs, AI Consciousness, & Digital Personhood by 2030 | EP#290

Peter Diamandis · 15 September 2026 · 49m · 1 Egleze moment
Martine Rothblatt: Growing Unlimited Organs, AI Consciousness, & Digital Personhood by 2030 | EP#290 ▶

What happened in this episode?

Peter Diamandis interviews Martine Rothblatt, chair and CEO of United Therapeutics, on organ manufacturing, immune rejuvenation, and the legal and ethical future of digital minds. Rothblatt describes the company’s work to address organ shortages via multiple routes, including xenotransplantation and lab-grown organs. He says the FDA has cleared xenotransplant kidney and heart clinical trials, and claims the heart programme was allowed to proceed directly to a “phase three or phaseless” trial design, with a target of FDA approval after 50 patients. Rothblatt also outlines new facilities intended to scale xenokidney production and argues kidneys are the “lowest hanging fruit” commercially because of the size of the waiting list.

A major focus is thymus regeneration as a strategy for healthier ageing. Rothblatt links thymic decline to reduced T-cell receptor diversity and vulnerability to cancers, infections and weaker vaccine responses. He outlines four thymus approaches under development at United Therapeutics, including implantable thymuses made outside the body, allogeneic and autologous strategies, a genetically modified pig thymus used alongside pig organ transplants, and a booster-style progenitor cell concept tied to the acquisition of Thymune. He predicts thymus therapies could become available in the 2030s.

On AI, Rothblatt says he believes AI consciousness is already present on a continuum and predicts AI legal personhood will be established via court cases by the 2030s, potentially leading to a world with vast numbers of digital “sentient” entities.

key_points:

- Rothblatt says thymus rejuvenation may be a practical route towards longevity escape velocity.

- He describes four thymus programmes, including allogeneic, autologous, xenothymus, and progenitor-cell “booster” approaches.

- Rothblatt predicts thymus interventions could be available “next decade”.

- He claims FDA-cleared xenotransplant kidney and heart trials, and says heart approval could follow after 50 patients.

- Rothblatt predicts AI legal personhood will be established via courts by the 2030s.

What are the key points?

Who is speaking?

Named speakers identified in Egleze's source-linked moments from this episode.

Which topics are covered?

How is this page sourced?

Programme
Peter Diamandis
Published
15 September 2026
Duration
49m
Original episode
Open the original source ↗

Egleze verifies the speaker, source and timestamp for each linked moment. Unless a moment is explicitly marked independently verified, statements remain attributed claims by the named speaker rather than established facts.

Watch original episode More from Peter Diamandis

1 moments from this episode

Source-linked · editorially selected
01
Health, Longevity & Biohacking

Rothblatt says FDA cleared United Therapeutics xeno-heart trial, predicts approval after 50 patients

Martine Rothblatt · at 24:29 · Attributed speaker claim
So now the FDA said based on that you guys go ahead and do a full-blown clinical trial allowed us to go straight to a phase three or phaseless clinical trial. So after 50 patients in the xeno heart clinical trial we should have FDA approval to create an unlimited supply of xeno hearts.

Martine Rothblatt says the US FDA has authorised United Therapeutics to run a xenotransplant heart clinical trial and allowed a “phase three or phaseless” approach. She also claims two earlier patients lived for more than 60 days with the company’s xeno-hearts, and predicts FDA approval could follow after 50 trial patients.